Sofia Forssten

Sofia Forssten


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Archives of Oral Biology
Verified
Journal Article
Closed access
KSKrista Salli
Krista Salli
SFSofia Forssten
Sofia Forssten
SLS.J. Lahtinen
S.J. Lahtinen
AOArthur Ouwehand
Arthur Ouwehand

1 December 2013 in Appetite
Verified
Journal Article
Closed access
SFSofia Forssten
Sofia Forssten
MKMarta Z. Korczyńska
Marta Z. Korczyńska
RZRenate M.L. Zwijsen
Renate M.L. Zwijsen
WNWouter H. Noordman
Wouter H. Noordman
MMMari Madetoja
Mari Madetoja
AOArthur Ouwehand
Arthur Ouwehand

13 January 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
SFSofia Forssten
Sofia Forssten
AOArthur Ouwehand
Arthur Ouwehand
The probiotic definition stipulates “adequate amounts”. Here, we investigated the metabolic output and recovery rate of probiotic strains using a simulated upper gastro-intestinal passage and colonic fermentation. Two different doses, 7 × 109 colony forming units (CFU) and 7 × 1010 CFU, of a probiotic mixture (Bifidobacterium lactis Bl-04, Lactobacillus acidophilus La-14, Lactobacillus paracasei Lpc-37, and Lactobacillus plantarum Lp-115) or placebo were tested. The four strains were quantified by qPCR and the metabolites analyzed by gas chromatography. There was a dose-response in the detection of all four strains. There was a slightly larger increase between the two doses for L. paracasei Lpc-37 as compared with the other strains; this may suggest a greater robustness of this strain. Compared with the placebo, the high dose simulations generated more propionic acid and a higher total of short chain fatty acids (SCFA). Higher doses of a species are required to reach measurable increases above the baseline level of this species.

13 October 2015 in Microbial Ecology in Health and Disease
Verified
Journal Article
Open access
PDF file
SFSofia Forssten
Sofia Forssten
HRHenna Röytiö
Henna Röytiö
AHAshley Hibberd
Ashley Hibberd
AOArthur C. Ouwehand
Arthur C. Ouwehand
The effect of polydextrose and probiotic lactobacilli in a Clostridium difficile -infected human colonic model

3 May 2021 in Applied Sciences
Verified
Journal Article
Open access
PDF file
YYYuan Yue
Yuan Yue
DNDitte S. G. Nielsen
Ditte S. G. Nielsen
SFSofia Forssten
Sofia Forssten
KKKnud Erik Bach Knudsen
Knud Erik Bach Knudsen
MSMarkku T. Saarinen
Markku T. Saarinen
SPStig Purup
Stig Purup
Many functional food ingredients improve intestinal barrier function through their colonic fermentation products short chain fatty acids (SCFAs). Effects of individual SCFAs have been well studied, but the effects of SCFA mixtures–colonic fermentation products have been rarely investigated. Therefore, this study used an EnteroMix semi-continuous model to simulate the colonic fermentation of three widely used food ingredients, polydextrose, lactitol and xylitol in vitro, and investigated the effects of their fermentation products on impaired colonic epithelial barrier function through a mucus-secreting human HT29-MTX-E12 cell model. Fermentation of polydextrose and lactitol produced mainly acetate, while fermentation of xylitol produced mainly butyrate and resulted in a much higher butyrate proportion. All fermentation products significantly improved intestinal barrier repairing as measured by increased transepithelial electrical resistance and decreased paracellular permeability. Among these, xylitol fermentation products exhibited better repairing effects than that of polydextrose and lactitol. Correlation analysis showed that the repairing effects were attribute to butyrate but not acetate or propionate, implying that in the fermentation products butyrate may play a major role in improving intestinal barrier function. Our results suggest that functional food ingredients that mainly produce butyrate during fermentation may be of more value for improving gut health related to chronic diseases.

9 April 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
SFSofia Forssten
Sofia Forssten
NYNicolas Yeung
Nicolas Yeung
AOArthur Ouwehand
Arthur Ouwehand
The present study aimed to investigate whether probiotic recovery is affected when consumed together with antibiotics. Fecal samples were collected from an earlier antibiotic associated diarrhea, randomized, placebo-controlled study with a product consisting of a combination of Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, and Bifidobacterium lactis Bi-07, B. lactis Bl-04 at equal numbers and at a total dose of 1010 CFU. Fecal samples were collected during the screening visit (T0), i.e., at the time of antibiotic prescription, and then on the last day of the antibiotic treatment (T1) as well as seven days after the subject had stopped taking the antibiotic treatment (T2) and at two weeks after completing antibiotic treatment and one week after probiotic/placebo consumption stopped (T3). Samples were analyzed for the presence of the four administered strains. The study was registered at clinicaltrials.gov as NCT01596829. Detection levels of all four strains were significantly increased from T0 to T1 and returned to baseline level from T2 to T3. There were also significantly more subjects with detectable levels of L. paracasei Lpc-37, B. lactis Bi-07, and B. lactis Bl-04 at T1 and T2 compared to T0 and T3, and compared to placebo. Each of the four strains could be detected in the feces of patients apparently unaffected by the simultaneous consumption of antibiotics.